NCT05681039View on ClinicalTrials.gov

Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

PHASE2RecruitingINTERVENTIONAL

Enrollment

29

Participants

Timeline

Start Date

June 2, 2023

Primary Completion Date

November 1, 2026

Study Completion Date

November 1, 2026

Conditions

Squamous Cell CarcinomaOral Cavity Squamous Cell Carcinoma

Interventions

DRUG

Tiragolumab

Given by IV (vein)

DRUG

Atezolizumab

Given by IV (vein)

BEHAVIORAL

Standard of Care

after care from surgery

BEHAVIORAL

Questionnaires

Quality of life

RADIATION

Cisplatin

Given by IV (vein)

RADIATION

Carboplatin

Given by IV (vein)

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER